ATE389712T1 - Krebs immuntherapie mit semi-allogenen zellen - Google Patents

Krebs immuntherapie mit semi-allogenen zellen

Info

Publication number
ATE389712T1
ATE389712T1 AT98904782T AT98904782T ATE389712T1 AT E389712 T1 ATE389712 T1 AT E389712T1 AT 98904782 T AT98904782 T AT 98904782T AT 98904782 T AT98904782 T AT 98904782T AT E389712 T1 ATE389712 T1 AT E389712T1
Authority
AT
Austria
Prior art keywords
cells
semi
allogene
cancer immunotherapy
allogeneic
Prior art date
Application number
AT98904782T
Other languages
English (en)
Inventor
Edward P Cohen
Original Assignee
Edward P Cohen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Edward P Cohen filed Critical Edward P Cohen
Application granted granted Critical
Publication of ATE389712T1 publication Critical patent/ATE389712T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT98904782T 1997-01-31 1998-01-30 Krebs immuntherapie mit semi-allogenen zellen ATE389712T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3662097P 1997-01-31 1997-01-31

Publications (1)

Publication Number Publication Date
ATE389712T1 true ATE389712T1 (de) 2008-04-15

Family

ID=21889646

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98904782T ATE389712T1 (de) 1997-01-31 1998-01-30 Krebs immuntherapie mit semi-allogenen zellen

Country Status (7)

Country Link
US (3) US6187307B1 (de)
EP (1) EP1012240B1 (de)
JP (1) JP2001522226A (de)
AT (1) ATE389712T1 (de)
CA (1) CA2278678A1 (de)
DE (1) DE69839273T2 (de)
WO (1) WO1998033527A2 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998033527A2 (en) * 1997-01-31 1998-08-06 Cohen Edward P Cancer immunotherapy with semi-allogeneic cells
US6503503B1 (en) * 1997-05-13 2003-01-07 Duke University Allogeneic cellular vaccine
WO2000076537A2 (en) * 1997-09-10 2000-12-21 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of semi-allogeneic cell line-peptide complexes for the treatment of cancer, aids and other viral diseases
AU2001251034A1 (en) * 2000-03-31 2001-10-15 Gene Logic, Inc Gene expression profiles in esophageal tissue
AU2002225681A1 (en) * 2000-11-15 2002-05-27 Globe Immune, Inc. Yeast-dentritic cell vaccines and uses thereof
DE10112851C1 (de) 2001-03-16 2002-10-10 Gsf Forschungszentrum Umwelt Semi-allogene Antitumor-Vakzine mit HLA-haplo-identischen Antigen-präsentierenden Zellen
US7955845B2 (en) * 2001-11-20 2011-06-07 Dana Farber Cancer Institute, Inc. Modified antigen-presenting cells
EP1509244B1 (de) * 2002-06-06 2011-07-27 Immunicum AB Neues verfahren und zusammensetzung zur herstellung einer zellulären allogenen vakzine
US8343502B2 (en) * 2002-12-16 2013-01-01 Globeimmune, Inc. Yeast-based vaccines as immunotherapy
US7439042B2 (en) * 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
KR101241272B1 (ko) 2002-12-16 2013-03-15 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 면역 요법으로서의 효모계 백신
WO2004064785A2 (en) 2003-01-14 2004-08-05 Dana Farber Cancer Institute Cancer therapy sensitizer
US8420603B2 (en) * 2004-05-14 2013-04-16 Abraxis Bioscience, Llc SPARC and methods of use thereof
AU2006249235B2 (en) 2004-05-14 2010-11-11 Abraxis Bioscience, Llc Sparc and methods of use thereof
EP2460533A3 (de) 2004-10-18 2014-01-08 Globeimmune, Inc. Therapeutikum auf Hefebasis gegen chronische Hepatitis-C-Infection
WO2006112930A2 (en) * 2005-02-18 2006-10-26 Abraxis Bioscience, Inc. Q3 sparc deletion mutant and uses thereof
CA2603191A1 (en) * 2005-03-29 2006-10-05 The Board Of Trustees Of The University Of Illinois Cancer vaccines and therapeutic methods
EP2268306A2 (de) * 2008-03-14 2011-01-05 The Board Of Trustees Of The University Of Illinois Therapeutische krebsantigene
WO2009129205A2 (en) * 2008-04-14 2009-10-22 Abraxis Bioscience, Llc Sparc anti-inflammatory activity and uses thereof
US8728489B2 (en) 2008-09-19 2014-05-20 Globeimmune, Inc. Immunotherapy for chronic hepatitis C virus infection
CN102272153B (zh) 2008-11-24 2015-04-15 德国慕尼黑亥姆霍兹研究中心健康和环境有限公司 高亲和力t细胞受体及其应用
US20120009203A1 (en) * 2010-06-29 2012-01-12 Anahid Jewett Depletion of cancer stem cells
US9763982B2 (en) 2010-06-29 2017-09-19 The Regents Of The University Of California Depletion of cancer stem cells
JP2018090491A (ja) * 2015-04-01 2018-06-14 株式会社細胞治療技術研究所 癌ワクチンの製造方法、及び癌ワクチン
JP2020516654A (ja) 2017-04-13 2020-06-11 センティ バイオサイエンシズ インコーポレイテッド 組み合わせがん免疫療法
US10636512B2 (en) 2017-07-14 2020-04-28 Cofactor Genomics, Inc. Immuno-oncology applications using next generation sequencing
US11419898B2 (en) 2018-10-17 2022-08-23 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
TW202035685A (zh) 2018-10-17 2020-10-01 美商聖堤生物科技股份有限公司 組合癌症免疫療法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674486A (en) 1991-06-25 1997-10-07 San Diego Regional Cancer Center Cancer immunotherapy with carrier cells
CA2121127A1 (en) 1991-10-25 1993-04-29 Robert E. Sobol Lymphokine gene therapy of cancer
IL105008A0 (en) 1992-03-13 1993-07-08 Yeda Res & Dev Double transfectants of mhc genes as cellular vaccines for immunoprevention of tumor metastasis
EP0569678A3 (de) 1992-03-13 1994-10-26 Yeda Res & Dev Mit MHC-Genen doppelt transfizierte Zellen als Impfstoffe zur Immunoprevention von Tumormetastasen.
US5759535A (en) 1994-05-13 1998-06-02 Research Corporation Technologies, Inc. Immunotherapeutic strategies for the treatment of cancer
US6022538A (en) 1995-06-06 2000-02-08 The Wistar Institute Of Anatomy And Biology Method of treating malignancies
UY24367A1 (es) * 1995-11-23 2000-10-31 Boehringer Ingelheim Int Vacunas contra tumores y procedimiento para su produccion
US6805869B2 (en) 1996-06-12 2004-10-19 Shanghai Cp Guojian Pharmaceutical Co., Ltd. Cellular vaccines and immunotherapeutics and methods for their preparation
US6277368B1 (en) * 1996-07-25 2001-08-21 The Regents Of The University Of California Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine
US6063375A (en) 1996-09-10 2000-05-16 Medical University Of South Carolina Semiallogeneic cell hybrids and related methods for treating cancer
GB9620350D0 (en) 1996-09-30 1996-11-13 Maudsley David J Cancer vaccine
WO1998033527A2 (en) 1997-01-31 1998-08-06 Cohen Edward P Cancer immunotherapy with semi-allogeneic cells
DE60128070T2 (de) 2000-02-14 2008-01-10 The Regents Of The University Of California, Oakland Impfstoff spezifisch gegen nierentumore, gerichtet gegen das antigen g-250 des nierentumors
US7060802B1 (en) 2000-09-18 2006-06-13 The Trustees Of Columbia University In The City Of New York Tumor-associated marker
CA2603191A1 (en) 2005-03-29 2006-10-05 The Board Of Trustees Of The University Of Illinois Cancer vaccines and therapeutic methods

Also Published As

Publication number Publication date
US6187307B1 (en) 2001-02-13
DE69839273T2 (de) 2009-03-05
WO1998033527A2 (en) 1998-08-06
DE69839273D1 (de) 2008-04-30
US20080305131A1 (en) 2008-12-11
CA2278678A1 (en) 1998-08-06
EP1012240B1 (de) 2008-03-19
WO1998033527A3 (en) 1998-11-05
US7402306B1 (en) 2008-07-22
EP1012240A2 (de) 2000-06-28
US7670611B2 (en) 2010-03-02
JP2001522226A (ja) 2001-11-13

Similar Documents

Publication Publication Date Title
DE69839273D1 (de) Krebs immuntherapie mit semi-allogenen zellen
Shimizu et al. Enhancement of tumor lysate-and peptide-pulsed dendritic cell-based vaccines by the addition of foreign helper protein
Tähtinen et al. Exploiting preexisting immunity to enhance oncolytic cancer immunotherapy
Mesa et al. Challenges facing adjuvants for cancer immunotherapy
TR200100936T2 (tr) Terapötik aşılama
CA2267157A1 (en) Cancer immunotherapy using tumor cells combined with mixed lymphocytes
CA2203991A1 (en) Methods and devices for immunizing a host to tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
Raez et al. Lung cancer immunotherapy
Pampena et al. Natural killer cells as helper cells in dendritic cell cancer vaccines
SG46445A1 (en) Vaccines against cancer and infectious diseases
CY1106400T1 (el) Συνθεση και μεθοδος ανοσοθepαπειας με καρκινικο αντιγονο
LV12085A (lv) Dendritiskas sunas stimulejosais faktors
EA200300092A1 (ru) Применение лигандов молекул мнс класса ii в качестве адъювантов для вакцинации и lag-3 в лечении злокачественных опухолей
CA2253632A1 (en) Compositions and methods for treating cancers and pathogen infections using antigen-presenting cells loaded with rna
Assudani et al. In vivo Expansion, Persistence, and Function of Peptide Vaccine–Induced CD8 T Cells Occur Independently of CD4 T Cells
ZA200401842B (en) Process for the maturation of dentritic cells and a vaccine.
Geary et al. Tumor immunotherapy using adenovirus vaccines in combination with intratumoral doses of CpG ODN
NZ507829A (en) Vaccine adjuvants for immunotherapy of melanoma
WO2002053176A3 (en) An autologous anti-cancer vaccine
PT1171587E (pt) Peptido derivado do antigenio muc-1 para desencadear uma reaccao imunitaria contra celulas tumorais
Mulé Dendritic cell‐based vaccines for pancreatic cancer and melanoma
Conforti et al. Update on active specific immunotherapy with melanoma vaccines
Dezfouli et al. Enhancing CTL responses to melanoma cell vaccines in vivo: synergistic increases obtained using IFNγ primed and IFNβ treated B7‐1+ B16‐F10 melanoma cells
AU2005314271B2 (en) Alpha thymosin peptides as cancer vaccine adjuvants
DE60130634D1 (de) Identifizierung von antigenen peptiden durch zytotoxische t-lymphozyten aktiviert von dendritischen zellhybriden

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties